Joint strategy sets direction for EMA and EU medicines regulatory agencies to 2025
EMA and the Heads of Medicines Agencies (HMA) have published their joint strategy for the next five years, following its recent adoption by the HMA and EMA Management Board.
The strategy details how the European medicines regulatory network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges posed by ever-accelerating developments in science, medicine, digital technologies, globalisation as well as emerging health threats, such as the COVID-19 pandemic.
The European medicines agencies network strategy to 2025 outlines six priority areas for the network:
• the availability and accessibility of medicines;
• data analytics, digital tools and digital transformation;
• antimicrobial resistance and other emerging health threats;
• supply chain challenges; and
• the sustainability of the network and operational excellence.
The network will review the strategy after 18 months to consider if the goals and objectives remain appropriate, and to adjust them if necessary, in the light of the changing environment and ongoing engagement with stakeholders.
For more details and related content please click here.